Questcor Pharmaceuticals (Nasdaq: QCOR ) reported earnings on July 30. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Questcor Pharmaceuticals beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly. GAAP earnings per share expanded significantly.
Gross margins dropped, operating margins grew, net margins grew.
Questcor Pharmaceuticals booked revenue of $184.6 million. The nine analysts polled by S&P Capital IQ expected to see sales of $169.0 million on the same basis. GAAP reported sales were 64% higher than the prior-year quarter's $112.5 million.
EPS came in at $1.12. The six earnings estimates compiled by S&P Capital IQ averaged $0.96 per share. GAAP EPS of $1.12 for Q2 were 72% higher than the prior-year quarter's $0.65 per share.
For the quarter, gross margin was 90.7%, 360 basis points worse than the prior-year quarter. Operating margin was 55.8%, 150 basis points better than the prior-year quarter. Net margin was 37.5%, 60 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $177.6 million. On the bottom line, the average EPS estimate is $1.04.
Next year's average estimate for revenue is $666.2 million. The average EPS estimate is $3.72.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 505 members out of 558 rating the stock outperform, and 53 members rating it underperform. Among 153 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 131 give Questcor Pharmaceuticals a green thumbs-up, and 22 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Questcor Pharmaceuticals is outperform, with an average price target of $52.44.
- Add Questcor Pharmaceuticals to My Watchlist.